that could create barriers and delays for people, even those who qualify for anti-viral treatment for covid-19, says the organization that represents pharmacists in the province.
that is especially crucial because there is a narrow window during which paxlovid, the common anti-viral treatment for covid-19, is most effective, said jen belcher, a pharmacist who is vice-president of strategic initiatives and member relations with the ontario pharmacists association.
“if the patient is approaching the end of their time window for paxlovid initiation, delays in testing could leave some patients who would otherwise qualify for therapy ineligible due to the requirement that paxlovid be initiated within five days of symptom onset,” said belcher.
because patients should receive the anti-viral treatment within five days of the onset of symptoms, timing can be crucial, said belcher, as the treatment prevents severe illness. earlier in the pandemic, many people who were at risk for severe outcomes were unable to access paxlovid because of delays in getting assessments and testing.
she also said the cost of purchasing test kits for those who don’t qualify for free testing or treatment could be prohibitive “or very challenging for our most socio-economically vulnerable patients, leaving them with fewer choices for testing and therefore potential access barriers.”